Pharma major Lupin today announced a new partnership with Eli Lilly India to market and sell the latter’s diabetes treatment drug ‘Eglucent’ in the country.
“According to the agreement, Lupin will market and sell Eglucent through its own specialty field force while Lilly will be responsible for manufacturing and import,” Lupin said in a BSE filing. It further said: “Eli Lilly and Company (India) Pvt Ltd (Lilly) will continue to sell Lispro under the brand name Humalog through its existing channels”. Lupin had earlier collaborated with Lilly in July, 2011 to promote and distribute Lilly’s Huminsulin range of products in India and Nepal. Eli Lilly and Company (India) Pvt Ltd is a subsidiary of the US pharmaceutical major Eli Lilly and Company.